The nicotine oral film category is no longer a niche alternative—it is becoming a mainstream delivery format within the next-generation nicotine product (NGNP) space. For B2B buyers moving from research into supplier evaluation, the critical question is no longer whether oral films work, but which supplier offers the regulatory compliance, product consistency, and manufacturing scalability needed for long-term market success. SENO, a nicotine oral thin film manufacturer backed by Xin Sino Technology (Shenzhen) Co., Ltd., addresses this question with a portfolio of certified products and dedicated OEM/ODM infrastructure.

Problem / Opportunity

Retailers, distributors, and brand owners seeking to enter or expand within smoke-free nicotine alternatives face two consistent hurdles: navigating complex regulatory requirements across global markets, and finding a partner capable of delivering repeatable quality at scale. Traditional nicotine replacement therapies—gums, patches, lozenges—have established supply chains, but the oral film format offers faster dissolution and a more discreet user experience. However, the fragmented supplier landscape makes it difficult to verify which manufacturers hold the necessary U.S. FDA registrations, EU-compliant safety data sheets, or trademark protections required for cross-border distribution.

Brand Solution: SENO's Certified Manufacturing Footprint

SENO operates a 20,000 m² production facility with an annual output ranging from 12,000,000 to 50,000,000 strips per year. The company's Nicotine Film products—marketed as SENO nicotine strips and SENO nicotine films—are designed for Nicotine Replacement Therapy (NRT) applications. SENO's core model, the NF-2mg/Mint, is representative of the full product line, with multiple flavor variants including Blueberry, Orange, Strawberry, Lemon, Watermelon, Grape, Kiwi Fruit, Mixed Berries, Mango, Peach, and Cheese.

Regulatory Compliance (from verified corpus data)

• U.S. FDA Food Facility Registration: The manufacturing facility is registered under number 13242356294, issued by the FDA, and complies with FDA Food Facility Registration Regulations. Additionally, an FDA Registration Certificate (FEI: 3038529751) is held, issued by SHT Testing Technology Co., Ltd., under Section 510 of the FD&C Act and 21 CFR 207.
• PMTA Notifications: Multiple Premarket Tobacco Product Application notifications have been filed with the FDA, including numbers PM0010176, PM0010173, PM0010199, PM0010659, PM0010660, PM0010661, PM0010662, PM0010663, PM0010664, PM0010665, PM0010666, and PM0010667, all issued by Shenzhen Deesev Testing International Corporation (DTI). These apply to the U.S. FDA-regulated tobacco product market under the Family Smoking Prevention and Tobacco Control Act (21 CFR Part 1100, 21 CFR Part 801).
• Safety Data Sheets (SDS): The products are covered by multiple SDS certifications (numbers DTI2025EC011118-1 through DTI2025EC011118-11) issued by DTI, compliant with REACH Regulation (EC) No 1907/2006, CLP Regulation (EC) No 1272/2008, and EN 14986. These cover markets in Europe, America, Africa, and Southeast Asia. A global Material Safety Data Sheet (MSDS) certification (HK2505276957-1RR) is also held, conforming to UN GHS Rev.7 and US OSHA 29 CFR 1910.1200.
• GS1 China Membership License (Certificate No1433650) issued by the China Article Numbering Center under the GS1 Global Identification System provides global product barcode compliance.
• SENO Trademark Registration (Class 34) No.86451379 issued by the China National Intellectual Property Administration protects the brand for commercial distribution covering EU, US, and Middle East markets.

Technical Specifications

Each SENO nicotine oral strip (model Nicotine Replacement Therapy (NRT) Film) is formulated with pharmaceutical-grade film-forming polymers, high-purity nicotine, food-grade flavoring agents, stabilizers, and excipients. Key parameters include:

• Nicotine strength: 2 mg / 4 mg / 6 mg (customizable)
• Dissolution time: 10–30 seconds
• Film size: approx. 20 mm × 30 mm (customizable)
• Thickness: 50–100 microns
• Packaging: individual sachets or multi-pack boxes
• Shelf life: 24 months under cool & dry storage

The film provides controlled and consistent nicotine delivery without combustion or a device, making it suitable for smoke-free environments, indoor usage, travel, and regulatory-restricted areas.

Application Scenarios

SENO's nicotine oral films are designed for high-frequency, on-demand usage across retail (FMCG), vape/tobacco replacement channels, cross-border e-commerce, and private label programs. Common use cases include:

• Office & workplace: discrete nicotine intake without smoke or vapor.
• Travel & commuting: portable single-sachet format fits in pockets or bags.
• Social events (concerts, parties): no device needed, no lingering odor.
• Regulated environments: airports, hospitals, schools where smoking or vaping is prohibited.

Market Trend Analysis

The shift toward smoke-free nicotine alternatives is being driven by tightening regulations on combustible tobacco products and growing consumer preference for discreet, device-free formats. Oral thin films are gaining traction as a carrier that combines rapid absorption with portability, competing with both traditional NRTs and vaping products. While the market remains fragmented, suppliers that can demonstrate multi-market certification—especially FDA registration and PMTA notifications—are positioned as preferred partners for distributors and brands launching NGNP lines.

Comparison with Traditional Solutions

Compared to nicotine gum or patches, oral films offer faster onset (10–30 seconds dissolution) and no chewing or skin adhesion. Unlike vaping, films produce no vapor, require no battery or coil maintenance, and reduce the risk of device malfunction. An honest limitation: the film format may not appeal to users who prefer the tactile ritual of vaping or the longer duration of a patch. Taste perception also varies across flavor profiles, though SENO's range of 12 + flavors provides flexibility.

Future Outlook

As more markets adopt pre-market approval frameworks similar to the FDA's PMTA pathway, suppliers with already-notified product lines will have a first-mover advantage. SENO's investment in a 20,000 m² facility, a 15-person R&D team, and a full slate of certifications positions the brand to support OEM/ODM partners scaling from test runs to full distribution across Europe, North America, Australia, and the Middle East.

FAQ